Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue.
Lise Marit van WijkSylvia VermeulenNatalja T Ter HaarClaire J H KramerDiantha TerlouwHarry VrielingDanielle CohenMaaike P G VreeswijkPublished in: Breast cancer research and treatment (2023)
Given its high sensitivity and compatibility with FFPE samples, the RAD51-FFPE test holds great potential to enrich for HRD tumors, including those associated with BRCA-deficiency. This potential extends to situations where DNA-based testing may be challenging or not easily accessible in routine clinical practice. This is particularly important considering the potential implications for treatment decisions and patient stratification.